SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending due to excitement surrounding its AI strategy and potential partnerships, especially after the CEO's presentation. The community is actively discussing the company's prospects in AI, data centers, and autonomous vehicles, with many bulls dismissing bearish sentiments and eyeing a $200 target. Positive sentiment seems to be fueled by new partnerships and the anticipation of further developments in the AI sector.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending after a strong earnings report and raised guidance, though the stock experienced a dip, typical post-earnings. The community is actively discussing potential catalysts like upcoming rate cuts and S&P inclusion, with some speculating about a possible buyout. Despite the volatility, many investors express long-term confidence in SoFi's growth.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is surging due to a newly announced partnership with OpenAI, which will integrate the payment platform into ChatGPT, sparking excitement about AI-driven commerce. Community members are also encouraged by positive earnings and the initiation of a dividend, seeing this as a catalyst for renewed growth and a higher stock price. Discussions highlight the potential for PayPal to capitalize on the growing adoption of AI in the financial technology sector.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as investors discuss the start of Gravity SUV deliveries in Canada and a recent award for the Lucid Air Sapphire. Despite positive milestones, the community remains concerned about dilution, production targets, and the company's cash burn. Discussions also include potential partnerships and overall sentiment regarding the EV sector.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending after Nvidia announced a $1 billion investment, with community members discussing the potential impact on AI-driven networking and 6G technology. Bullish sentiment is fueled by the strategic partnership and the belief that Nokia is undervalued, while some traders are taking profits and expressing caution about potential dilution. The investment aims to integrate Nvidia's AI chips with Nokia's 5G/6G software.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The QQQ is trending as the market continues its upward momentum, fueled by enthusiasm around AI and hopes for upcoming rate cuts and a potential US-China trade deal. Community members are debating whether this rally is sustainable or a bubble waiting to burst, with some noting the strength of big tech while others express concern about overall economic conditions.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending amid a new partnership with the Vegas Golden Knights and anticipation for their humanoid robot reveal at the NVIDIA GTC conference this week. Community chatter revolves around the potential impact of AI and robotics on live sports and hospitality, with some investors expressing excitement for long-term growth. Concerns remain about short-term volatility and the need for further sales catalysts.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth is trending as traders digest the latest earnings report, which beat expectations but revealed rising medical costs impacting profits. The community is actively debating the implications of these costs, along with membership growth and future outlook, while some speculate about market manipulation and potential for a rebound to higher price targets. Discussions also include comparing UNH to other trending tickers and considering the influence of major investors like Warren Buffett.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending amid discussions of a potential short squeeze and increased buyback program, with community members debating its legitimacy and future prospects. Some investors express frustration with the stock's sideways movement despite positive news and contracts, while others remain optimistic, citing the company's cash position and potential for growth in the AI sector. The stock's low float and upcoming earnings are also key points of discussion.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid excitement surrounding a potential partnership with Nvidia, with community members speculating on the impact of Jensen Huang's comments and a possible Trump meeting. Some are pointing to RBC's reiterated underperform rating and high valuation metrics, while others highlight the company's growing presence in government and commercial sectors ahead of earnings next week. Community members are debating the stock's valuation and potential for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS (voclosporin) at the...

Aurinia Pharmaceuticals on Monday pushed back on criticism of its lupus drug Lupkynis (voclosporin) by a top FDA official who had raised questions about the medicine’s clinical benefit in a LinkedIn post that has since been deleted.Shares of Aurinia tumbled 16% to $11.06, marking their worst day since February 2024, before recovering 4% in after-hours trading to $11.51.In a statement, Aurinia reiterated its positive outlook for Lupkynis, stating that it has an established benefit–risk profile. Aurinia highlighted that the drug was granted full FDA approval in January 2021 following the AURORA 1 study, and received additional approval in April 2024 based on data from the AURORA 2 study, which demonstrated its efficacy and safety over a three-year period.The selloff followed a post by George Tidmarsh, director of the FDA’s drug center, who said Lupkynis “has not been shown to provide a direct clinical benefit for patients.” His comments were part of a broader discussion about the agency’s use of surrogate endpoints, which are biological measures used to accelerate drug approvals, that he said had led to both “notable successes and failures.”The post drew widespread attention not only for its criticism of a specific drug and company, something regulators almost never do publicly, but also for its choice of platform.&nbsp;Soon after media reports surfaced, Tidmarsh deleted the post and clarified that his comments were “personal views” that “do not reflect those of the FDA or HHS,”&nbsp; adding that all official communications would continue to be made through formal agency channels.On Stocktwits, retail sentiment for Aurinia was ‘extremely bullish’ amid a&nbsp;whopping 10,040% surge in 24-hour message volume.One user said the stock’s decline wasn’t surprising, describing it as a healthy pullback after a strong run that could set up the next move higher.<stembedurl>https://stocktwits.com/Itsagame999/message/630423873</stembedurl>Other users expressed frustration with the company’s response, saying they had expected a stronger reaction and were disappointed by what they described as a brief, generic statement, with one adding they had lost $70,000 on the drop.<stembedurl>https://stocktwits.com/timfris/message/630421172</stembedurl><stembedurl>https://stocktwits.com/Dallas9/message/630420635</stembedurl><a href="https://stocktwits.com/symbol/AUPH">Aurinia’s stock</a> has risen 23.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aurinia’s stock (AUPH) has risen 23.2% so far in 2025. (Photo credit: Getty Images)

Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery

The company reiterated its confidence in Lupkynis’ long-term efficacy and safety following its approval and the submission of supplementary data.

Equity

Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options

Investors need to pay close attention to AUPH stock based on the movements in the options market lately.

Retail chatter around Aurinia Pharmaceuticals picked up pace late Sunday, with investors eyeing an update on the company’s early-stage AUR200 trial targeting autoimmune conditions later in the day.The experimental therapy, first dosed in healthy volunteers in September 2024, is being evaluated in a single ascending dose study.&nbsp;The program is assessing safety, tolerability, drug behavior in the body, and biomarker response.&nbsp;AUR200 works by targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), proteins involved in immune system regulation.&nbsp;The company has said it plans to pursue one broader indication and one rare disease, both with relatively few existing treatments.&nbsp;Funding for development is coming from Aurinia’s current cash flow.In May,&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia</a> reported new findings from its Phase 3 AURORA 1 study of Lupkynis (voclosporin), its approved treatment for lupus nephritis.&nbsp;The post-hoc analysis suggested&nbsp;that patients receiving triple therapy with Lupkynis, mycophenolate mofetil (MMF), and low-dose steroids achieved better proteinuria outcomes than those on MMF and steroids alone.&nbsp;&nbsp;Adverse event rates were comparable between groups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they wouldn’t be selling even if the stock hit $10, saying they were “in it for the big bucks.”&nbsp;<stembedurl>https://stocktwits.com/RedBarnCannabis/message/619401660</stembedurl>Another pointed out that historically, strong data has moved the stock significantly and stated that with Aurinia’s sizable cash reserves, dilution concerns were minimal, adding that they were hoping for double-digit gains following the update.<stembedurl>https://stocktwits.com/timfris/message/619390483</stembedurl>The stock has declined 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Company News for May 13, 2025

Shares of Aurinia Pharmaceuticals Inc. (AUPH) surged 3% in premarket trading on Monday after the company’s first-quarter (Q1) earnings topped Wall Street expectations.The biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250512965572/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2025">reported</a> a 24% year-on-year (YoY) jump in its first-quarter (Q1) total revenue to $62.5 million, surpassing an analyst estimate of $61.06 million, according to Finchat data.The surge in revenue was primarily driven by a 25% YoY jump in net product sales of Lupkynis, the company’s FDA-approved oral therapy for treating adult patients with active lupus nephritis, to $60 million.For the three months ending March 31, 2025, the company reported a net income of $23.3 million, compared to a loss of $10.7 million in 2024.Diluted earnings per share came in at $0.16 for the quarter, compared to a loss of $0.07 per share recorded in the corresponding period of 2024, and above an analyst estimate of $0.1. &nbsp;&nbsp;&nbsp;&nbsp;Aurinia ended the quarter with cash, cash equivalents, restricted cash, and investments of $312.9 million, compared to $358.5 million on Dec. 31, 2024.CEO Peter Greenleaf said the company looks forward to a “strong performance” in 2025.The firm also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.On Stocktwits, retail sentiment around Aurinia jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:632/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_12_at_7_28_54_AM_png_b95ef3aeed.webp" alt="AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits" width="632" height="60"><figcaption>AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down by about 9% this year but up by over 59% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/expedia-retail-traders-remain-optimistic-despite-q1-revenue-miss/chiNeqjRbme">Expedia Retail Traders Remain Optimistic Despite Q1 Revenue Miss Ahead Of Holiday Travel Season</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$12.57
Prev Close	$12.29
Open	$12.27
Dividend Yield	0.00%
50-Day Moving Average	$12.05
Beta	1.08
Avg. Volume	1.95M
PE Ratio	28.74

52-Week High	$13.54
52-Week Low	$6.55
Market Capitalization	$1.62B
EPS (Annual)	$0.0393
Price to Book	4.86
Revenue Per Employee	$1.81M
Enterprise Value/EBITDA	N/A

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc